E Fund Management Co. Ltd. Purchases Shares of 10,238 Emergent BioSolutions Inc. (NYSE:EBS)

E Fund Management Co. Ltd. purchased a new stake in Emergent BioSolutions Inc. (NYSE:EBS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 10,238 shares of the biopharmaceutical company’s stock, valued at approximately $98,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. SBI Securities Co. Ltd. acquired a new stake in shares of Emergent BioSolutions in the fourth quarter worth $63,000. Stifel Financial Corp bought a new stake in Emergent BioSolutions in the 3rd quarter valued at $96,000. FORA Capital LLC acquired a new stake in Emergent BioSolutions in the 3rd quarter worth $103,000. Landscape Capital Management L.L.C. bought a new position in shares of Emergent BioSolutions during the 3rd quarter worth about $141,000. Finally, Entropy Technologies LP bought a new position in shares of Emergent BioSolutions during the 3rd quarter worth about $155,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EBS has been the topic of a number of recent research reports. StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Emergent BioSolutions in a report on Tuesday, March 4th.

Emergent BioSolutions Price Performance

Shares of EBS stock opened at $5.77 on Monday. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The stock’s fifty day simple moving average is $9.33 and its 200 day simple moving average is $8.94. Emergent BioSolutions Inc. has a one year low of $1.82 and a one year high of $15.10. The firm has a market cap of $313.25 million, a price-to-earnings ratio of -1.41 and a beta of 1.80.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.40. The firm had revenue of $194.70 million during the quarter, compared to the consensus estimate of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same period last year, the firm posted ($0.77) EPS. On average, analysts expect that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.